Hepatitis B vaccination. Indications about postvaccination antibody testing and booster doses;Vacunación de la hepatitis B. Indicaciones del test serológico postvacunal y la dosis de refuerzo

Revista Espanola de Salud Publica

Volumn 74, Issue 5-6, 2000, Pages 475-482

  Álvarez, José Ramón Pallás ^a,d   Holgado, María Soledad Gómez ^b   Díaz, Javier Llorca ^a   Rodríguez, Miguel Delgado ^c  

^a Univenidad de Cantabria   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c UNIVERSITY OF JAÉN   (Spain)

^d NONE   (Spain)

Author keywords

Booster dose; Hepatitis B immunology; Hepatitis B vaccine; Hepatitis B serology

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE;

ANTIBODY DETECTION; CHILD; FOLLOW UP; HEALTH CARE PERSONNEL; HEPATITIS B; HIGH RISK PATIENT; HUMAN; IMMUNOLOGICAL MEMORY; PRACTICE GUIDELINE; PRESCHOOL CHILD; REVIEW; SCHOOL CHILD; SEROLOGY; TREATMENT INDICATION; VACCINATION;

EID: 18844468979     PISSN: 11355727     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. A controlled clinical trial of the efficacy of the hepatitis B vaccine (heptavax B): A final report
2. Immune responses to late booster doses of hepatitis B vaccine
3. Strategies for immunisation against hepatitis B in western Europe
4. Threeweek hepatitis B immunity in vaccinated health care works
5. Recommendations of the Immunisation Practices Advisory Committee. Recommendations for protection against viral hepatitis
6. Hepatitis B vaccination: How long does protection last?
7. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men
8. Four years experience with a recombinant hepatitis B vaccine
9. Long term results of hepatitis B vaccination in patients on dialysis
10. Hepatitis B vaccine in infants from an endemic area: Long term anti-HBs persistence revaccination
11. Recombinant yeast hepatitis B vaccine compared with plasma-derived vaccine: Immunogenicity and effect of a booster dose
12. Is booster injection with hepatitis B vaccine necessary in healthy responders? A study of the immune response
13. Protection provided by hepatitis B vaccine in a Yupik Eskimo population: Results of a 10-year study
14. Increases in levels of antibody to hepatitis B surface antigen in a immunized population
15. Immunogecity of two recombinant hepatitis B vaccines in older individuals
16. Kinetics of antibody response to hepatitis B virus determinants and to recombinant vaccines in Italy
17. Vaccine induced immunologic memory for hepatitis B surface antigen: Implications for policy on booster vaccination
18. Correlation between in vivo humoral and in vitro cellular immune responses following immunisation with hepatitis B surface antigen (HbsAg) vaccines
19. Immune response to hepatitis B revaccination
20. Hepatitis B vaccine: Prospects for duration of immunity
21. Prospects for control of hepatitis B virus infection: Implications of childhood vaccination and long-term protection
22. Persistence of specific antibodies after hepatitis B vaccination
23. Acute hepatitis B after vaccination
24. Genetic prediction of nonresponse to hepatitis B vaccine
25. Hepatitis B vaccine in patients receiving hemodialysis: Immunogenicity and efficacy
26. Hepatitis B vaccination in ederly
27. Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV-infected individuals
28. Response to an extra dose of hepatitis B vaccine and specific antibody persistence in nonresponders to primary immunisation
29. Hepatitis B in nonresponder to hepatitis B vaccine
30. Hepatitis B revaccination of neonates with inadequate response after primovaccination
31. Early immunisation with hepatitis B vaccine: A five-year study
32. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C
33. Is there a need for boosters of hepatitis B vaccine
34. Booster immunization of low- and non-responders after a standard three dose after hepatitis B vaccine schedule. Results of a post-marketing surveillance
35. Hepatitis B vaccine boosting among young healthy adults
36. Are booster immunisations needed for lifelong hepatitis B immunity?
37. The IgG subclass profile of anti-HBs response in vaccinated children and children seroconverted after natural infection
38. Long-term efficacy of immunization against hepatitis B virus in infants at high-risk analyzed by polymerase chain reaction
39. Comparative immunogenicity under field conditions of two recombinant hepatitis B vaccines in 8-10-year-old children
40. Vaccines to prevent viral hepatitis
41. Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccinations. Recommendations of the Immunization Practices Advisory Committee (ACIP)
42. Immunisation against hepatitis B-what can we expect? Results of a survey of antibody response to immunisation in persons 'at risk' of occupational exposure to hepatitis B
43. Persistence of anti-HBs antibodies in health care personnel vaccinated with plasma-derived Hepatitis B vaccine and response to recombinant DNA HB booster vaccine
44. Serologic hepatitis B immunity in vaccinated health care workers
45. Coinfections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users
46. Intravenous drug users serologic control: What may be prevented?
47. Methadone-maintained former heroin addicts, including those who are anti-HIV-1 Seropositive, comply with and respond to hepatitis B vaccination
48. Hepatitis B vaccines in patients with chronic renal failure
49. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load
50. Hepatitis B vaccine: An overview
51. Comparison of two immunization schedules with recombinant hepatitis B vaccine and natural immunity acquired by hepatitis B infection in dialysis patients